Le, X., Patel, J. D., Shum, E., Baik, C., Sanborn, R. E., Shu, C. A., Kim, C., Fidler, M. J., Hall, R., Elamin, Y. Y., Tu, J., Blumenschein, G., Zhang, J., Gibbons, D., Gay, C., Mohindra, N. A., Chae, Y., Boumber, Y., Sabari, J., Santana-Davila, R., Rogosin, S., Herzberg, B., Creelan, B., Pellini, B., Tanvetyanon, T., Heeke, S., Hernandez, M., Gray, J. E., Saltos, A., Heymach, J. V. (2025). A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve
                    <i>EGFR</i>
                    -Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial). Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.00533